{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:37:05Z","timestamp":1789043825607,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BRAAVE (NCT03631732), a Phase 3b, multicenter, open\u2010label US study, demonstrated the efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) among Black individuals with suppressed HIV through 48 weeks. Here, 72\u2010week resistance, adherence, and virologic outcomes are presented. Enrollment criteria permitted nonnucleoside reverse transcriptase inhibitor (NNRTI)\u2013resistance (R), protease inhibitor (PI)\u2013R, and certain nucleos(t)ide reverse transcriptase inhibitor (NRTI)\u2013R (M184V\/I allowed; \u22653 thymidine analog mutations [TAMs] excluded); but excluded primary integrase strand transfer inhibitor (INSTI)\u2010R. Pre\u2010existing resistance was determined using historical genotypes and retrospective baseline proviral DNA genotyping. Adherence, virologic outcomes, and viral blips were assessed. Of 489 participants receiving B\/F\/TAF with \u22651 post\u2010switch HIV\u20101 RNA measurement: pre\u2010existing NRTI\u2010R (15% of participants), M184V\/I (11%), \u22651 TAMs (8%), NNRTI\u2010R (22%), and PI\u2010R (13%) were observed; pre\u2010existing INSTI\u2010R substitutions (2%) were detected post\u2010randomization; mean viral blip frequency was 0.9% across all timepoints (unassociated with virologic failure); 24% of participants had &lt;95% adherence (98% of whom had HIV\u20101 RNA\u00a0&lt;50 copies\/mL at last visit); none had treatment\u2010emergent study\u2010drug resistance. Overall, 99% of participants, including all with baseline NRTI\u2010R\/INSTI\u2010R, had HIV\u20101 RNA\u00a0&lt;50 copies\/mL at the last visit, demonstrating that B\/F\/TAF maintained virologic suppression through 72 weeks regardless of pre\u2010existing resistance, viral blips, and suboptimal adherence.<\/jats:p>","DOI":"10.1002\/jmv.29899","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T03:05:04Z","timestamp":1728270304000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["High efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in Black adults in the United States, including those with pre\u2010existing HIV resistance and suboptimal adherence"],"prefix":"10.1002","volume":"96","author":[{"given":"Kristen","family":"Andreatta","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"D'Antoni","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyappa","family":"Parvangada","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Blair","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Hagins","sequence":"additional","affiliation":[{"name":"Chatham CARE Center  Savannah Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princy","family":"Kumar","sequence":"additional","affiliation":[{"name":"Georgetown University  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Hindman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States 2017\u20132021: National Profile HIV Surveillance Supplemental Report. 2023;28(3).https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/impact-on-racial-and-ethnic-minorities#:~:text=Black%2FAfrican%20American%20and%20Hispanic%2FLatino%20communities%20are%20disproportionately%20affected but%20accounted%20for%2040%25%20of%20people%20with%20HIV"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30019-4"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2020.0008"},{"key":"e_1_2_11_5_1","unstructured":"Gilead Sciences. Biktarvy Prescribing Information. 2022. Accessed July 12 2023.https:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/biktarvy\/biktarvy_pi.pdf"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101991"},{"key":"e_1_2_11_11_1","unstructured":"AndreattaK ChangS DelaneyM et al. Long\u2010term efficacy among participants switched to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir\/abacavir\/lamivudine with preexisting resistance and viral blips.\u00a0Presented at: 11th IAS Conference on HIV Science; 2021; Virtual."},{"key":"e_1_2_11_12_1","unstructured":"AndreattaK ChangS DelaneyM et al. Long\u2010term efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide after switch from boosted protease inhibitor\u2010based regimens including in those with preexisting resistance and viral blips.\u00a0Presented at: 18th European AIDS Conference; 2021; London UK."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002731"},{"issue":"3","key":"e_1_2_11_14_1","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV\u20101","volume":"27","author":"Wensing AM","year":"2019","journal-title":"Top Antivir Med"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00419-5"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003244"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002454"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173892"},{"issue":"18","key":"e_1_2_11_20_1","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study","volume":"18","author":"Haas DW","year":"2004","journal-title":"AIDS"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1120-8"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12134"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663843"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002850"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-20"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/378281"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3478-3484.2003"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28723"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02557-19"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.29899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.29899","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.29899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:13:54Z","timestamp":1777706034000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.29899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/jmv.29899"],"URL":"https:\/\/doi.org\/10.1002\/jmv.29899","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29899"}}